LONDON (Reuters) - Recent U.S. tax changes have weakened the case for companies like Pfizer to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's chief executive.



















source Reuters: Business News http://ift.tt/1pputI2